ALVIN BURSTEIN: Open Payments
NPI 1962553412 · SCOTTSDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,734 in 74 payments from 17 companies in 2025. Trend: 2023 $5,921 · 2024 $2,478 · 2025 $1,734
Food & beverage: $1,384Consulting: $350
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $294 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $262 |
| Otsuka America Pharmaceutical, Inc. | 9 | $167 |
| ABBVIE INC. | 11 | $162 |
| JAZZ PHARMACEUTICALS INC. | 1 | $150 |
| Vanda Pharmaceuticals Inc. | 5 | $105 |
| Lundbeck LLC | 4 | $82 |
| Alkermes, Inc. | 3 | $81 |
| Corium, LLC | 4 | $71 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $67 |
Products named: CAPLYTA, LUMRYZ, REXULTI, VRAYLAR, XYWAV, FANAPT, LYBALVI, Azstarys.
Industry payments across AZ — which companies pay providers there.
